

Review of: "A Review of the Scientific Literature on Experimental Toxicity Studies of COVID-19 Vaccines, with Special Attention to Publications in Specific Toxicology Journals"

Sankha Shubhra Chakrabarti¹

¹ Banaras Hindu University

Potential competing interests: No potential competing interests to declare.

This is an important piece of work and should be developed as a full paper, and the author should attempt to get it published. It is quite unfortunate, as the authors have pointed out, that very few of the toxicology journals published anything of note with regard to the preclinical studies of COVID-19 vaccines.

1. The search terms used may be restated as smaller fragments with Boolean operators provided to enhance reproducibility of the search strategy. If it was a general search based on the experience of the author instead of a systematized strategy, the same should be mentioned.
2. It might be a good idea to tabulate the results for the different vaccines as tables for ease of understanding.
3. The vaccines may be arranged in the tables by type and also by relative use globally to give an idea of the extent of preclinical toxicology studies for the most used vaccine types.
4. Whether animal pharmacokinetic studies dealing with the persistence of vaccines in the body and dissemination within the body have been performed may be discussed for each vaccine type (optionally in detail, else as a short paragraph).
5. The author may provide a comparison of the well-studied (preclinically) and the poorly studied (preclinically) vaccines.
6. Whether the toxicology studies were published after the human trials and after mass vaccination needs to be highlighted, and the relevance of this finding should be discussed. To me, it seems most toxicology studies deal with the less used or obscure vaccines not used for mass administration and were published long after mass vaccination was completed.
7. For the ease of understanding of clinical doctors, it would be a good idea to separate the Results section into articles dealing with the major vaccines used in mass administration and those which reached only the development stage but were never used in the population.
8. The author mentions that mRNA vaccine manufacturers have published few toxicology studies. Have these been published by the AdenoV and inactivated vaccine manufacturing companies? Or have they been published only by independent researchers? In case all manufacturers have been deficient, singling out mRNA vaccine makers may not be prudent.

